Observational studyNaunyn-Schmiedeberg's archives of pharmacology2026
Efficacy and safety of baloxavir marboxil vs. oseltamivir in Chinese outpatients with influenza B: an IPTW-adjusted real-world cohort study.
Observational study in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baloxavir marboxil (baloxavir) shows satisfactory efficacy and safety for treating influenza, particularly influenza A. However, real-world evidence for influenza B in Chinese populations is scarce. This study aimed to explore the efficacy and safety of baloxavir vs. oseltamivir in Chinese outpatients with influenza B. This real-world cohort study included 811 outpatients with influenza B between November 2023 and January 2024, comprising 394 patients in the baloxavir group and 417 patients in the oseltamivir group. Inverse probability of treatment weighting (IPTW) was applied to minimize potential confounding and achieve covariate balance. In both unweighted and IPTW-weighted cohorts, time to fever resolution was shorter in the baloxavir group (median: 24.0 h) compared with the oseltamivir group (median: 48.0 h) (both P < 0.001). In both cohorts, the baloxavir group (median: 120.0 h) had a shorter time to symptom resolution than the oseltamivir group (median: 168.0 h) (both P < 0.001). Due to residual imbalance, time from symptom onset to antiviral initiation was adjusted for in the multivariable Cox model. After adjustment, the baloxavir group remained associated with faster fever resolution and symptom resolution (all P < 0.001). The incidence of any adverse events was lower in the baloxavir group than in the oseltamivir group (3.6% vs. 10.3%) (P < 0.001). Headache was more frequent (1.3% vs. 0.0%), whereas nausea (0.0% vs. 6.7%) and vomiting (0.0% vs. 6.5%) were less frequent in the baloxavir group vs. the oseltamivir group (all P < 0.05). Baloxavir achieves faster fever resolution and symptom resolution, with a better safety profile in Chinese outpatients with influenza B.
Indexed as
Identifiers
42319416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.